Screener
West Pharmaceutical Services WST Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000105770-26-000099
| (in millions, except per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Inventories | 447.4 | 443.9 |
| Other current assets | 212.3 | 168.6 |
| Total current assets | 1,807.5 | 1,978.2 |
| Property, plant and equipment | 3,248.6 | 3,223.4 |
| Less: accumulated depreciation and amortization | 1,562.3 | 1,497.0 |
| Property, plant and equipment, net | 1,686.3 | 1,726.4 |
| Operating lease right-of-use assets | 104.7 | 117.0 |
| Investments in affiliated companies | 207.7 | 212.3 |
Item 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is West Pharmaceutical Services's cumulative cost basis?
- West Pharmaceutical Services (WST) reported cumulative cost basis of $3.25B in Q2 2026.
- How has West Pharmaceutical Services's cumulative cost basis changed year-over-year?
- West Pharmaceutical Services's cumulative cost basis increased by 2.2% year-over-year, from $3.18B to $3.25B.
- What is the long-term trend for West Pharmaceutical Services's cumulative cost basis?
- Over 5 years (2020 to 2025), West Pharmaceutical Services's cumulative cost basis has grown at a 9.6% compound annual growth rate (CAGR), from $2.04B to $3.22B.
Ask your AI about West Pharmaceutical Services's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude